Mathematical Models of Cancer are More Reminiscent of Glasperlenspiel

Manfred Sneps-Sneppe

Abstract


The article has two goals: firstly, to attract the interest of mathematicians to immunology and, secondly, to make some efforts (it must be admitted that quite limited) to promote the key achievements of Latvian virologists in the invention of cancer research, namely, the medicines Rigvir and Larifan for that going back in history to the 1960s. The immune system (innate and adaptive immunity) as well as lymphocyte sources are discussed, namely, T cells, B cells, dendritic cells, cytokines, chemokines, and interferons. The dual role of macrophages and dendritic cells is studied in many mathematical models. Generally, cancers do not have danger signals and, therefore, cannot elicit strong immune reactions. Immunomodulators turn cancer from a cold to a hot state, to make cancer visible to the immune system. Immunomodulators Poly (I:C) and Larifan are compared. Oncolytic virus therapy is a novel approach in the field of cancer treatment. The first oncolytic virus in the world was the genetically unmodified ECHO-7 strain enterovirus Rigvir, which was approved in Latvia in 2004 for skin melanoma treatment, but withdrawn in 2019 because did not reach the current standards for clinical use within the EU area.


Full Text:

PDF

References


NCI Funding Trends. Available: 2022 NCI Budget Fact Book - Funding Trends - NCI (cancer.gov).

I. Kareva et al, “Predator-prey in tumor-immune interactions: A wrong model or just an incomplete one?” Frontiers in Immunology. 12:668221 (2021).

E. Kim et al, “Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models”. Cancers. 13, 823 (2021).

D.N. Santiago et al, “Fighting Cancer with Mathematics and Viruses”. Viruses. 9(9):239 (2017).

R. M Wood, J. R. Egan, I. M. Hall, “A dose and time response Markov model for the in-host dynamics of infection with intracellular bacteria following inhalation: with application to Francisella tularensis”. J. R. Soc. Interface.11: 20140119 (2014).

H. Brown, “Ilya Mechnikov and his studies on comparative inflammation”. Proc Soc Exp Biol Med. 209(2):99-101 (1995).

P. Valent, et al, “Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine”. J Innate Immun. 8 (2): 111–120 (2016).

“White blood cells”. Available: https://en.wikipedia.org/wiki/White_blood_cell

D. N. Hart, “Dendritic cells: unique leukocyte populations which control the primary immune response”. Blood. 90(9):3245-87 (1997).

[K. Liu, “Dendritic Cells”. Encyclopedia of Cell Biology. 741–9 (2016).

P. Kovarik, V Castiglia, M. Ivin and F. Ebner, “Type I Interferons in Bacterial Infections: A Balancing Act”. Front. Immunol. 7:652 (2016).

M. Marzagalli, N.D. Ebelt, E.R. Manuel, “Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment”. Seminars in cancer biology. Vol. 59, pp. 236-250 (2019). Academic Press.

A. Mantovani, et al, “Tumour immunity: effector response to tumor and role of the microenvironment”. The Lancet. 371, 9614,1–7 March, 771-783 (2008).

N.Y. den Breems, R. Eftimie, “The re-polarisation of M2 and M1 macrophages and its role on cancer outcomes”, J. Theor. Biol. 390, 23-39 (2016).

R. Eftimie, H. Hamam, “Modelling and investigation of the CD4+ T cells - Macrophages paradox in melanoma immunotherapies”. J Theor Biol. 420:82-104 (2017).

R. Eftimie, G. Eftimie, “Tumour-associated macrophages and oncolytic virotherapy: a mathematical investigation into complex dynamics”, Lett. Biomath. 5 (1) 70-99 (2018).

A.S. Moffett, Y. Deng, H. Levine, “Modeling the Role of Immune Cell Conversion in the Tumor-Immune Microenvironment”. Bulletin of Mathematical Biology 85:93 (2023).

E.D. Danilenko, A.O. Belkina, and G.M. Sysoeva, “Development of Drugs Based on High-Polymeric Double-Stranded RNA for Antiviral and Antitumor Therapy”. Biochem. Moscow Suppl. Ser. B. 13, 308–323 (2019).

A.K. Field, A.A. Tytell, G.P. Lampson, M.R. Hilleman, “Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes”. Proceedings of the National Academy of Sciences, 1004-1010 (1967).

J. De Waele, et al, “A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy”. Journal of Experimental & Clinical Cancer Research. 40:213 (2021).

D. Pjanova, L. Mandrika, R. Petrovska, Kr. Vaivode, S. Donina, “Comparison of the effects of bacteriophage-derived dsRNA and poly(I:C) on ex vivo cultivated peripheral blood mononuclear cells”, Immunology Letters, Vol 212 (2019).

M. Bifulco, E.D. Zazzo, F. Napolitano, et al. “History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses”. Biochimie. Vol 206 (March 2023).

S. Farkona, E.P. Diamandis, I.M. Blasutig, “Cancer immunotherapy: the beginning of the end of cancer?” BMC Med 14, 73 (2016).

P. Alberts, A. Tilgase, A. Rasa, et al, “The advent of oncolytic virotherapy in oncology: The Rigvir story”. European Journal of Pharmacology. Vol 837, 117-126 (15 Oct 2018).

E. Hietanen, M.K.A. Koivu, P. Susi, “Cytolytic Properties and Genome Analysis of Rigvir Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates”. Viruses.14(3):525 (2022 Mar 4).

P. Alberts, “Comment on Hietanen et al. Cytolytic Properties and Genome Analysis of Rigvir Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates. Viruses 2022, 14, 525”. Viruses, 14, 2076 (2022).

E. Hietanen, P. Susi, “Reply to Alberts, P. “Comment on Hietanen et al. Cytolytic Properties and Genome Analysis of Rigvir Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates. Viruses 2022, 14(3), 525”. Viruses.14(9):2078 (2022 Sep 19).

M. Sneps-Sneppe, D. Namiot, “Machine Learning – Could It Help in the Rigvir Case?” Proceedings 34th Conference of Open Innovations Association FRUCT (Nov 2023). Vol. 34, no. 2 https://doi.org/10.5281/zenodo.10426340


Refbacks

  • There are currently no refbacks.


Abava  Кибербезопасность MoNeTec 2024

ISSN: 2307-8162